Pulse Biosciences filings document regulatory disclosures for a Delaware medical technology company developing nPulse nanosecond pulsed field ablation technology. Its 8-K reports cover clinical and Regulation FD disclosures for the nPulse Cardiac Catheter System, atrial fibrillation study updates, investor presentation materials, and development priorities in electrophysiology, cardiac surgery, and soft tissue ablation.
The company's SEC record also includes proxy materials on board governance, executive compensation, equity awards, and shareholder voting matters. Other filings address capital structure, common stock financing arrangements, officer appointments, compensatory arrangements, operating and financial results, ownership matters, and risk factors tied to its technology development and clinical regulatory activities.
PULSE BIOSCIENCES, INC. director and major shareholder Robert W. Duggan reported an open-market purchase of 660,233 shares of common stock at $19.69 per share. After this purchase, he directly owns 48,370,047 common shares.
He also has indirect holdings of 630,109 shares through Genius 24C Inc. and 450,189 shares through Blazon Corporation, where he is the sole shareholder. The shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC and include approximately 700 shares that were previously omitted from a Schedule 14A.
Pulse Biosciences reported a net loss of $18.6M for the three months ended March 31, 2026, compared with $16.8M a year earlier, as it continues to invest heavily in its cardiac and soft-tissue ablation programs. Product revenue reached $0.4M, reflecting initial commercial sales of the Vybrance Percutaneous Electrode System.
Research and development expenses rose to $12.6M, while selling, general and administrative costs were $6.6M. Operating activities used $14.6M of cash. Cash and cash equivalents were $68.3M as of March 31, 2026, with an accumulated deficit of $481.9M.
The company initiated a 2026 strategic realignment to prioritize nsPFA electrophysiology catheters and cardiac devices for atrial fibrillation, reducing near-term spend on cardiac surgery market development and Vybrance sales and marketing. After quarter-end, it raised approximately $12.9M via an at-the-market share sale to its majority stockholder and CEO, and believes current resources and these proceeds can fund operations for at least one year past the financial statement issuance date.
Robert W. Duggan filed Amendment No. 17 to his Schedule 13D on Pulse Biosciences, Inc., reporting beneficial ownership of 49,706,423 shares of common stock, or 71.9% of the outstanding class.
The filing shows Duggan’s holdings include 256,078 options exercisable within 60 days, 630,109 shares held by Genius 24C Inc, and 450,189 shares held by Blazon Corporation, over which he may be deemed a beneficial owner. During the past 60 days, he purchased 660,233 shares at $19.69 per share through the company’s at-the-market equity offering program, funded with personal and entity working capital.
PULSE BIOSCIENCES, INC. director and Chief Executive Officer Paul A. LAVIOLETTE bought 15,000 shares of common stock in an open-market purchase on May 11, 2026 at $19.69 per share. After this transaction, he directly owns 15,846 shares of the company’s stock.
Footnotes explain the shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC, during an open trading window under the insider trading policy. His holdings also include shares purchased through the company’s Employee Stock Purchase Plan in March 2026.
PULSE BIOSCIENCES, INC. Chief Executive Officer Paul A. Laviollette purchased 15,000 shares of the company’s common stock in an open-market transaction. The shares were bought at a price of $19.69 per share and are held directly, bringing his direct ownership to 15,000 shares.
According to the disclosure, the shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC. The purchases occurred during an open trading window and in line with the company’s Insider Trading Policy and applicable securities laws.
PULSE BIOSCIENCES, INC. director and more than 10% owner Robert W. Duggan bought 660,233 shares of common stock in an open-market purchase at $19.69 per share. After this transaction, he directly owns 48,211,433 shares, with additional indirect holdings of 450,189 shares via Genius 24C Inc. and 630,109 shares via Blazon Corporation. The shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC and were purchased during an open trading window in line with the company’s insider trading policy.
Pulse Biosciences, Inc. is asking stockholders to vote at its 2026 virtual annual meeting on June 11, 2026, at 11:00 a.m. Eastern Time. The agenda includes electing seven directors to serve until the 2027 meeting and ratifying Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026.
The record date is April 28, 2026, with one vote per common share and a majority of outstanding shares required for a quorum. Robert W. Duggan beneficially owns 49,037,818 shares, or 71.6% of the common stock as of March 31, 2026. The proxy details board structure, committee membership, director compensation, equity incentive and inducement plans, a tightened insider trading policy, and related‑party financings, including a 2024 rights offering that raised $60 million.
Pulse Biosciences, Inc. reports that its Board of Directors has approved resolutions allowing TD Securities (USA) LLC, as sales agent under an existing Equity Distribution Agreement, to sell common stock to one or more company affiliates at the then current market trading price without a discount.
The Equity Distribution Agreement, dated February 19, 2026, permits at-the-market offerings of common stock with an aggregate offering price of up to $59,976,196. The company notes that Co-Chairman and major stockholder Robert Duggan, who beneficially owned approximately 72% of outstanding common stock as of March 31, 2026, and Chief Executive Officer and Co-Chairman Paul LaViolette have indicated they are likely to purchase shares in the near term, but without any binding commitments or specified amounts.
Pulse Biosciences reported first quarter 2026 results and clinical trial updates. For the three months ended March 31, 2026, revenue was $0.4 million and GAAP net loss was $18.6 million, compared to a net loss of $16.8 million a year earlier, as spending on clinical programs increased.
Total GAAP costs and expenses were $19.6 million, with research and development of $12.6 million and selling, general and administrative expenses of $6.6 million. Non-GAAP costs and expenses were $17.4 million and non-GAAP net loss was $16.4 million.
Cash and cash equivalents were $68.3 million as of March 31, 2026, with $14.6 million used in operating activities during the quarter. The company highlighted accelerated enrollment for its NANOPULSE-AF pivotal trial, now targeting completion in early Q4 2026, and plans to complete NANOCLAMP-AF enrollment by the end of the first half of 2027.
Pulse Biosciences filed an amended annual report mainly to add Part III information on directors, executive compensation, ownership, and governance, without updating financial results. The filing details a seven-member board, its committees, independence determinations, and a Strategic Advisory Committee focused on business strategy.
New CEO Paul A. LaViolette received 2025 total compensation of about $7.4 million, largely from performance- and market-based stock options with significant upside, while CFO Jon Skinner received about $2.8 million including a large start-date option. The compensation committee paid 2024 bonuses at 88.88% of target but granted no 2025 cash bonuses after determining 2025 corporate objectives were not achieved.
Ownership is highly concentrated: director Robert W. Duggan beneficially owns about 71.6% of common stock, and all directors and executive officers as a group hold about 74.7%. The company also outlines sizable option holdings for directors and executives and provides updated share reserves across its equity, ESPP, and inducement plans.